What Is a Millionaire-Maker Stock?
From time to time, investors will run across the term…
Sell
50
VRNA Quote, Financials, Valuation and Earnings
Last price:
$63.45
Seasonality move
:
16.62%
Day range:
$64.57 - $70.00
52-week range:
$11.39 - $74.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
24.89x
Volume:
2.3M
Avg. volume:
1.5M
1-year change:
345.3%
Market cap:
$5.6B
Revenue:
$42.3M
EPS (TTM):
-$2.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$54.8M | -$0.03 | -- | -99.24% | $94.10 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.6M | -$0.17 | -92.5% | -8.33% | $1.71 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.94 |
|
MREO
Mereo BioPharma Group PLC
|
$15.3M | -$0.01 | -100% | -71.23% | $7.44 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$66.26 | $94.10 | $5.6B | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.30 | $1.71 | $77.2M | -- | $0.00 | 0% | 0.43x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.41 | $17.94 | $3.6M | -- | $0.00 | 0% | 1.47x |
|
MREO
Mereo BioPharma Group PLC
|
$2.42 | $7.44 | $384.8M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$0.10 | $104.00 | $623.3K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
51.62% | 0.242 | 4.47% | 8.30x |
|
ADAP
Adaptimmune Therapeutics PLC
|
80.92% | 3.631 | 36.44% | 2.60x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 2.357 | -- | 1.20x |
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.393 | -- | -- |
|
NCNA
NuCana PLC
|
-- | -0.390 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$72.8M | -$10.3M | -51.07% | -85.84% | -8.34% | -$12.1M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$57.2M | -93.9% | -140.5% | -2197.67% | -$35.4M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$14.7M | -- | -- | -- | -$9.4M |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
Verona Pharma PLC vs. Competitors
-
Which has Higher Returns VRNA or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -21.4% compared to Verona Pharma PLC's net margin of -2303.38%. Verona Pharma PLC's return on equity of -85.84% beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC95.53% -$0.16 $468.3M ADAPAdaptimmune Therapeutics PLC-- -$0.31 $62.1M -
What do Analysts Say About VRNA or ADAP?
Verona Pharma PLC has a consensus price target of $94.10, signalling upside risk potential of 42.02%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.71 which suggests that it could grow by 468.75%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC7 0 0 ADAPAdaptimmune Therapeutics PLC2 3 0 -
Is VRNA or ADAP More Risky?
Verona Pharma PLC has a beta of 0.206, which suggesting that the stock is 79.434% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.857, suggesting its more volatile than the S&P 500 by 185.668%.
-
Which is a Better Dividend Stock VRNA or ADAP?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or ADAP?
Verona Pharma PLC quarterly revenues are $76.3M, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. Verona Pharma PLC's net income of -$16.3M is higher than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus 0.43x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $76.3M -$16.3M ADAPAdaptimmune Therapeutics PLC0.43x -- $3.2M -$74.2M
-
Which has Higher Returns VRNA or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -21.4% compared to Verona Pharma PLC's net margin of --. Verona Pharma PLC's return on equity of -85.84% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC95.53% -$0.16 $468.3M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About VRNA or BDRX?
Verona Pharma PLC has a consensus price target of $94.10, signalling upside risk potential of 42.02%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1172.62%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Verona Pharma PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC7 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is VRNA or BDRX More Risky?
Verona Pharma PLC has a beta of 0.206, which suggesting that the stock is 79.434% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.154, suggesting its more volatile than the S&P 500 by 15.371%.
-
Which is a Better Dividend Stock VRNA or BDRX?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or BDRX?
Verona Pharma PLC quarterly revenues are $76.3M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Verona Pharma PLC's net income of -$16.3M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus 1.47x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $76.3M -$16.3M BDRXBiodexa Pharmaceuticals PLC1.47x -- -- --
-
Which has Higher Returns VRNA or MREO?
Mereo BioPharma Group PLC has a net margin of -21.4% compared to Verona Pharma PLC's net margin of --. Verona Pharma PLC's return on equity of -85.84% beat Mereo BioPharma Group PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC95.53% -$0.16 $468.3M MREOMereo BioPharma Group PLC-- -$0.05 -- -
What do Analysts Say About VRNA or MREO?
Verona Pharma PLC has a consensus price target of $94.10, signalling upside risk potential of 42.02%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.44 which suggests that it could grow by 207.31%. Given that Mereo BioPharma Group PLC has higher upside potential than Verona Pharma PLC, analysts believe Mereo BioPharma Group PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC7 0 0 MREOMereo BioPharma Group PLC6 0 0 -
Is VRNA or MREO More Risky?
Verona Pharma PLC has a beta of 0.206, which suggesting that the stock is 79.434% less volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.465, suggesting its less volatile than the S&P 500 by 53.542%.
-
Which is a Better Dividend Stock VRNA or MREO?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or MREO?
Verona Pharma PLC quarterly revenues are $76.3M, which are larger than Mereo BioPharma Group PLC quarterly revenues of --. Verona Pharma PLC's net income of -$16.3M is lower than Mereo BioPharma Group PLC's net income of -$7M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $76.3M -$16.3M MREOMereo BioPharma Group PLC-- -- -- -$7M
-
Which has Higher Returns VRNA or NCNA?
NuCana PLC has a net margin of -21.4% compared to Verona Pharma PLC's net margin of --. Verona Pharma PLC's return on equity of -85.84% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC95.53% -$0.16 $468.3M NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About VRNA or NCNA?
Verona Pharma PLC has a consensus price target of $94.10, signalling upside risk potential of 42.02%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 100969%. Given that NuCana PLC has higher upside potential than Verona Pharma PLC, analysts believe NuCana PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC7 0 0 NCNANuCana PLC0 1 0 -
Is VRNA or NCNA More Risky?
Verona Pharma PLC has a beta of 0.206, which suggesting that the stock is 79.434% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.921%.
-
Which is a Better Dividend Stock VRNA or NCNA?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or NCNA?
Verona Pharma PLC quarterly revenues are $76.3M, which are larger than NuCana PLC quarterly revenues of --. Verona Pharma PLC's net income of -$16.3M is lower than NuCana PLC's net income of -$836.1K. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $76.3M -$16.3M NCNANuCana PLC-- -- -- -$836.1K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
99
DAVE alert for May 9
Dave [DAVE] is up 8.55% over the past day.
Buy
52
QDEL alert for May 9
QuidelOrtho [QDEL] is down 0.55% over the past day.
Buy
61
TPC alert for May 9
Tutor Perini [TPC] is up 7% over the past day.
